Journal: Stem Cell Research & Therapy

Article Title: hPMSCs inhibit the expression of PD-1 in CD4 + IL-10 + T cells and mitigate liver damage in a GVHD mouse model by regulating the crosstalk between Nrf2 and NF-κB signaling pathway

doi: 10.1186/s13287-021-02407-5

Figure Lengend Snippet: hPMSCs enhance Nrf2 expression but inhibit the activation of NF-κB in the GVHD mouse liver tissue. On day −5, Balb/c mice were conditioned using X-ray irradiation (8Gy); then, bone marrow cells and splenic mononuclear cells obtained from C57BL/6J mice were transplanted into the irradiated mice via injection into the tail vein. After 5 days, the mice demonstrated characteristics of GVHD at its peak (GVHD high ). Concurrently, PBS and hPMSCs were used to treat the GVHD high mice. The mice were then sacrificed to harvest the spleen and liver after treatment for 7 days for western blotting (WB). WB was performed to determine the expression of Nrf2, HO-1, NQO1, GCLC, and GCLM in the liver ( a , b ) and spleen ( c , d ) of GVHD mice in different groups ( n = 5). WB was performed to determine the expression of phosphorylated NF-κB and I-κB in the liver ( e , f ) and spleen ( g , h ) of GVHD mice in different groups ( n = 5). The results were obtained from three independent experiments * P <0.05, ** P < 0.01

Article Snippet: Antibodies for Nrf2, I-κB, p-NF-κB, p-I-κB, NQO1 (Abcam, Cambridge, UK), HO-1, NF-κB (Cell Signaling Technology, MA, USA), GCLC, and GCLM (Proteintech, Wuhan, China) were added to the membranes and the membranes were incubated overnight at 4°C.

Techniques: Expressing, Activation Assay, Irradiation, Injection, Western Blot

Journal: Stem Cell Research & Therapy

Article Title: hPMSCs inhibit the expression of PD-1 in CD4 + IL-10 + T cells and mitigate liver damage in a GVHD mouse model by regulating the crosstalk between Nrf2 and NF-κB signaling pathway

doi: 10.1186/s13287-021-02407-5

Figure Lengend Snippet: hPMSCs enhance Nrf2 levels but inhibit the activation of NF-κB in the mononuclear cells of GVHD mice. The mice were sacrificed to harvest the mononuclear cells of the spleen and liver after the treatment for 7 days for WB. WB was performed to determine the expression of Nrf2, HO-1, NQO1, GCLC, and GCLM in the mononuclear cells of the liver ( a , b ) and spleen ( c , d ) of GVHD mice in different groups ( n = 5). WB was performed to determine the expression of phosphorylated NF-κB and I-κB in the mononuclear cells of the liver ( e , f ) and spleen ( g , h ) of GVHD mice in different groups ( n = 5). The results were obtained from three independent experiments, * P < 0.05, ** P < 0.01

Article Snippet: Antibodies for Nrf2, I-κB, p-NF-κB, p-I-κB, NQO1 (Abcam, Cambridge, UK), HO-1, NF-κB (Cell Signaling Technology, MA, USA), GCLC, and GCLM (Proteintech, Wuhan, China) were added to the membranes and the membranes were incubated overnight at 4°C.

Techniques: Activation Assay, Expressing

Journal: Stem Cell Research & Therapy

Article Title: hPMSCs inhibit the expression of PD-1 in CD4 + IL-10 + T cells and mitigate liver damage in a GVHD mouse model by regulating the crosstalk between Nrf2 and NF-κB signaling pathway

doi: 10.1186/s13287-021-02407-5

Figure Lengend Snippet: hPMSCs induce the differentiation of CD4 + IL-10 + T cells by controlling the activation of the Nrf2 and NF-κB pathways. CD4 + IL-10 + T cells were induced, accompanied by changes in IL-2, IL-10, IL-27, and IFN-α2b levels in vitro, by using the naive CD4 + T cells treated with or without the Nrf2 inhibitor ML385 for 12 h, and then naive CD4 + T cells were cultured with or without hPMSCs and collected after 3 days for WB. a WB was performed to determine the expression of Nrf2, HO-1, NQO1, GCLC, and GCLM in the different CD4 + IL-10 + T cell differentiation systems in vitro. b qRT-PCR analysis of the expression of Nrf2, HO-1, NQO1, GCLC, and GCLM in the different CD4 + IL-10 + T cell differentiation systems in vitro. c WB was performed to determine the expression of phosphorylated NF-κB and I-κB in the different CD4 + IL-10 + T cell differentiation systems in vitro. The results were obtained from three independent experiments, * P < 0.05, ** P < 0.01

Article Snippet: Antibodies for Nrf2, I-κB, p-NF-κB, p-I-κB, NQO1 (Abcam, Cambridge, UK), HO-1, NF-κB (Cell Signaling Technology, MA, USA), GCLC, and GCLM (Proteintech, Wuhan, China) were added to the membranes and the membranes were incubated overnight at 4°C.

Techniques: Activation Assay, In Vitro, Cell Culture, Expressing, Cell Differentiation, Quantitative RT-PCR

Journal: Stem Cell Research & Therapy

Article Title: hPMSCs inhibit the expression of PD-1 in CD4 + IL-10 + T cells and mitigate liver damage in a GVHD mouse model by regulating the crosstalk between Nrf2 and NF-κB signaling pathway

doi: 10.1186/s13287-021-02407-5

Figure Lengend Snippet:

Article Snippet: Antibodies for Nrf2, I-κB, p-NF-κB, p-I-κB, NQO1 (Abcam, Cambridge, UK), HO-1, NF-κB (Cell Signaling Technology, MA, USA), GCLC, and GCLM (Proteintech, Wuhan, China) were added to the membranes and the membranes were incubated overnight at 4°C.

Techniques: Sequencing

Journal: Shock (Augusta, Ga.)

Article Title: Cardiac Progenitors Induced from Human Induced Pluripotent Stem Cells with Cardiogenic Small Molecule Effectively Regenerate Infarcted Hearts and Attenuate Fibrosis

doi: 10.1097/SHK.0000000000001133

Figure Lengend Snippet: According to treatment outline, the CPCs expressed CM, EC, SMC specific proteins. (A) CM progenitors expressed α-sarcomeric actinin, cTnI, MLC2v, cTnT and Cx43, scale bar = 50 μm. (B) Under TEM, these cells were rich in endoplasmic reticulum (ER) studded with ribosomes, developing myofilaments (mf), mitochondria (arrowhead) and glycogen particles. Nuclear chromatin material (N) was uniformly distributed in the nucleoplasm. (C) Endothelial progenitors expressed VE-cadherin and CD31, scale bar = 200 μm. LDL uptake by these cells was observed (D) and these also formed tube like structures (E). (F) Smooth muscle progenitors expressed a-SMA and calponin, scale bar = 200 μm. (G) FACS analysis revealed 95.2 ± 2.1% CMS, 90.3 ± 2.5% ECs and 92.3 ± 1.8% SMCs in basal differentiation medium.

Article Snippet: For endothelial cells (ECs) differentiation, culture medium was switched to EGM-2V medium (Lonza) for another 10days.

Techniques: